Lead Optimization

Lead optimization is where scientific insight, strategic decision-making, and data integration come together to transform promising leads into development-ready candidates. Beyond potency and selectivity, candidate selection requires evidence that a molecule can achieve the desired biological effect, demonstrate an acceptable safety profile, and translate successfully from preclinical studies to human trials. The candidates we deliver for clients have twice the industry average likelihood of achieving successful in vivo proof of concept studies in humans (Phase II).

Lead Optimization Services

We combine translational biology, biomarker strategies, early safety assessment, DMPK, pharmaceutical development and formulation, and therapeutic area expertise in lead optimization services to help you confidently identify the strongest candidates for progression.

ADME/DMPK

We pull together in silico prediction tools, ADME screening and DMPK to guide lead optimization and candidate selection for onward development.

Biomarkers

Identify and validate translational biomarkers that support clinical relevance and act as measurable indicators of therapeutic activity.

Physical Characterization and Pharmaceutics

Generate a thorough understanding of compound characteristics, such as crystallinity, stability and solubility, to inform pharmaceutical developability, formulation, and candidate selection.

Disease Biology & Pharmacology

To assess the effectiveness of drug action in the right disease context, we integrate preclinical drug efficacy, target validation, translational biomarkers and drug pharmacology studies.

Learn more

Human Safety NAMs

Improve the likelihood of clinical success with new approach methodologies (NAMs) that generate human-relevant safety insights across drug discovery programs.

Learn more

Process and Scale-Up Chemistry

Process chemistry optimization services and exploration of synthesis scale-up are essential to successful small molecule drug discovery and progression of lead optimization to candidate selection.

Translating PK/PD insights into Accurate Human Dose Predictions

Bridging Preclinical and Clinical Through Translational Biology

Human-Centric Safety Assessments That Clear the Path to IND

A viable development candidate must demonstrate robust pharmacokinetic and pharmacodynamic characteristics necessary to sustain clinical efficacy. Our streamlined capabilities rapidly translate early data into human dose projections.

ADME Assessment: In silico and empirical evaluation of absorption, distribution, metabolism, and excretion characteristics for compound developability.
In Vivo DMPK: Assessment of exposure, clearance, distribution, and pharmacokinetic behavior.
PK/PD Modeling: Understanding exposure-response relationships to support candidate differentiation.
Human Dose Prediction: Using translational modeling approaches to inform future clinical planning and guide development decisions.

Strong preclinical candidates require proof that their biological activity directly correlates to human disease. We connect your early discovery findings directly to future clinical endpoints, significantly reducing downstream uncertainty, and leverage deep translational expertise across oncology, neuroscience, immunology, metabolic, rare, and cardiovascular diseases:

Veteran Scientists: Disease-focused biology expertise, with many of our scientists having >15 years’ experience.
Target Engagement Strategies: We generate evidence that candidate molecules successfully bind and modulate intended targets and pathways.
Disease Relevant Systems: We use human cellular models to demonstrate biological relevance and confidently mirror complex patient biology.
Preclinical Pharmacology and Efficacy Services: drug efficacy and pharmacology studies demonstrate no just activity, but meaningful therapeutic impact.
Translational Biomarkers: Identify and validate critical biomarkers early to strengthen decision-making, clinical development strategies and to guide future human trial strategies.

Uncovering safety flaws during costly IND-enabling studies wastes vital time and capital. We integrate advanced screening protocols right at the start of lead optimization, allowing you to neutralize liability before it escalates.

Protect your timeline with our predictive de-risking strategies:

NAMs Platform: Deploy human-relevant New Approach Methodologies to replace outdated, less-predictive screens.
Early Toxicology: Uncover structural toxicities and off-target liabilities before selecting a final candidate.
Mechanistic Safety: Isolate and evaluate exact biological pathways driving adverse safety events.
Safety Biomarkers: Build custom human-centric assays to monitor and track potential safety risks.

3842_Scientist working in the Laboratory

Our Success Rates

Delivering Candidates with Double the Industry Average Proof of Concept Success

Candidate delivery represents the culmination of discovery research, in finding the right candidate with the optimal balance of desired properties to reach and modulate the target, and demonstrate therapeutic effects for the necessary duration without toxic side effects.

Rather than just identifying active compounds, we focus entirely on selecting molecules with the greatest potential to succeed in the clinic. We deliver candidates that have a success rate that is double the industry average in proof-of-concept (Phase II) clinical trials.

Why Choose Us For Lead Optimization and Candidate Delivery

We combine discovery, translational science, and asset development expertise into a single, connected scientific ecosystem. This connected approach helps you move from optimized lead candidates to development-ready assets with greater efficiency and confidence. Because we focus solely on client enablement, our goals are fully aligned with yours: delivering high-quality assets quickly.

• Embedded AI/ML: Integrating AI/ML and automating workflows to accelerate design cycles (5 day DMTA) cutting timelines to enable candidate delivery in as little as 18 months

• Predictive Power: Deploying high quality in silico models to forecast compound performance and triage even before synthesis.

• Elite Chemistry: Expert medicinal chemists specialized in knowledge-based drug design use an ‘in silico first’ approach via our proprietary Design and Predict Hub (AI/ML workflow platform) to expedite lead optimization. This supercharges the optimization of compound properties and candidate delivery.

• Unified Ecosystem: Integrating DMPK, medicinal chemistry and Knowledge-Based Drug Design/ modelling early safety, translational disease biology, and biomarkers experts, into a single stream.

• Translational and disease biology specialists: many of our scientists have >15 years’ experience in their expertise area.

• Human-relevant NAMs platform: de-risk and even eliminate safety liabilities early reducing costly failures later in the drug discovery process.

3226_Automation in the clinical laboratory. Pipetting robot laboratory. Medicine robotics.

What is lead optimization in drug discovery?

Lead optimization is the process of refining a promising lead compound to improve its overall drug-like properties while maintaining or enhancing biological activity. The goal is to balance potency, selectivity, pharmacokinetic properties, safety, and developability to identify a therapeutic that is both efficacious and safe, and can advance toward preclinical development and IND-enabling studies. Successful lead optimization relies on an iterative cycle of medicinal chemistry, biology, DMPK, and safety assessment.

How is lead optimization done?

Lead optimization services are selected based on individual drug discovery and development projects but commonly include medicinal chemistry, artificial-intelligence (AI) based optimization, predictive modeling using computer aided drug design (CADD), absorption, distribution, metabolism, and excretion (ADME)/drug metabolism and pharmacokinetics (DMPK) studies, mechanism of action (MoA) research, and formulation studies.

Effective lead optimization requires close collaboration across multiple scientific disciplines. By integrating expertise across these functions, our teams can rapidly address liabilities, prioritize compounds, and accelerate progression toward candidate delivery.

How do you determine when a lead is ready for candidate nomination?

A lead is considered ready for candidate nomination when it meets predefined project criteria aligned with the Target Product Profile (TPP). This typically includes demonstrated efficacy, acceptable ADME and pharmacokinetic properties, a favorable safety profile, suitable selectivity, and a scalable synthesis route. Candidate selection is driven by an integrated assessment of all available data, ensuring the molecule has the highest probability of success in clinical development.

How long does lead optimization take?

The timeline for lead optimization varies depending on target complexity, chemical series quality, biological understanding, and project objectives. While every program is unique, an experienced and integrated discovery team can shorten development timelines through efficient decision-making, parallel study execution, and continuous optimization of chemistry and biology workflows.

Lead Optimization